SLC5A2 and diabetes mellitus: Despite the improved prognosis of diabetes with the advent of sodium glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists, a great number of patients with diabetes still develop renal failure and the risk of death remains high [3]; so much so that diabetes and chronic kidney disease are among the top 10 causes of mortality in the US [4].